The Werner Syndrome ATP Dependent Helicase pipeline drugs market research report outlays comprehensive information on the Werner Syndrome ATP Dependent Helicase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Werner Syndrome ATP Dependent Helicase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology which include the indications Unspecified Cancer, and Solid Tumor. It also reviews key players involved in Werner Syndrome ATP Dependent Helicase targeted therapeutics development with respective active and dormant or discontinued products.
The Werner Syndrome ATP Dependent Helicase pipeline targets constitutes close to nine molecules. Out of which, approximately nine molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical, and Discovery stages are 1, 2, and 6 respectively.
Werner Syndrome ATP Dependent Helicase overview
Werner Syndrome ATP Dependent Helicase (WRN) is an enzyme that has both magnesium and ATP-dependent DNA-helicase activity and 3′->5′ exonuclease activity towards double-stranded DNA with a 5′-overhang. WRN plays an important role in the dissociation of joint DNA molecules that can arise as products of homologous recombination, at stalled replication forks or during DNA repair. WRN also plays a role in the formation of DNA replication focal centers; stably associates with foci elements generating binding sites for RP-A.
For a complete picture of Werner Syndrome ATP Dependent Helicase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
